Advancing In Vivo Detection of T‑Cell Function: Development and Preclinical Evaluation of ⁸⁹Zr‑Ivuxolimab, a Human OX40 PET Tracer

Kalita M
Stanford University
July 24, 2025
J Nucl Med
https://pubmed.ncbi.nlm.nih.gov/40707142

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/40707142

Research summary

The study developed and validated ⁸⁹Zr-labeled ivuxolimab, an anti-human OX40 antibody, for PET imaging of activated T cells. Using splenocytes isolated from human OX40 Knockin mice, it was possible to correlate tracer accumulation with T-cell activation in a graft-versus-host disease (GVHD) model. Ex vivo and in vivo PET/CT analyses confirmed high specificity and functional readout of OX40 engagement.

Key outcome of the study

⁸⁹Zr‑ivuxolimab binds activated T cells in vivo, enables longitudinal imaging of OX40⁺ populations in inflammatory models, supports translational development of OX40-targeted immunotherapies

Model

Human OX40 Knockin mouse — genOway-developed, expressing human OX40 (TNFRSF4) to replace mouse OX40, allowing in vivo detection of human OX40 with ⁸⁹Zr-ivuxolimab

TARGET:
Tnfrsf4
Synonyms:
OX40, CD134, ACT35, TXGP1L, Ly-63

Keywords

Immuno-PET imaging, T cell activation, humanized immune targets, GVHD model, translational imaging biomarkers

Technical specifications

Human OX40 gene Knockin, replacement of murine Tnfrsf4 with human sequence, PET tracer (⁸⁹Zr‑ivuxolimab), GVHD-induced activation model, in vivo T cell tracking, radiolabeling and biodistribution

Related products

Catalogue product

genO-hOX40

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

Customized product

No items found.

Catalogue product

No items found.
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe